Pfizer has sold 54.7 % of its stake in German biopharmaceutical company BioNTech SE, a transaction that involved 4.55 million American depositary receipts priced between $108 and $111.70 each. The sale is expected to generate approximately $508 million for Pfizer and was executed as an overnight block trade on November 13 2025.
Prior to the sale, Pfizer owned about 1.52 % of BioNTech’s shares, a position that was reduced to a residual holding of 1.66 million ADSs valued at roughly $163.5 million. The divestiture does not alter the governance structure of BioNTech, which remains majority‑owned by AT Impf GmbH and Medine GmbH, who together hold nearly 60 % of the company.
Pfizer’s decision to liquidate a large portion of its BioNTech stake is part of a broader capital‑allocation strategy aimed at refocusing on its core pipeline and addressing upcoming patent cliffs. The move follows the company’s $10 billion acquisition of obesity‑focused startup Metsera and comes as Pfizer seeks to strengthen its position in high‑growth therapeutic areas.
For BioNTech, the sale does not change the terms of its long‑standing collaboration with Pfizer, which continues to underpin the COVID‑19 vaccine program and other joint vaccine initiatives. The company’s oncology pipeline, which includes more than 40 candidates and four Phase 3 trials, remains on track, and its mRNA platform continues to be a key driver of future growth.
Pfizer’s Q3 2025 earnings report, released earlier this month, showed a 6 % decline in revenue to $16.7 billion but an adjusted EPS of $0.87 that beat consensus estimates of $0.64 by $0.23. The beat was largely attributed to disciplined cost management and a favorable mix of high‑margin products. In response, Pfizer raised its full‑year adjusted EPS guidance to $3.00–$3.15, signaling confidence in its cost‑control trajectory.
BioNTech’s Q3 2025 results, announced on November 3, revealed revenue of €1.52 billion—well above the €979.5 million forecast—driven by a €1.5 billion partnership payment from Bristol Myers Squibb. The company posted a net loss of €28.7 million but raised its full‑year revenue guidance to €2.6–€2.8 billion, underscoring its continued investment in oncology and mRNA research.
Pfizer CEO Albert Bourla said the company’s “adjusted earnings are performing well, and we are raising the range of our adjusted diluted EPS guidance for the full year.” BioNTech CFO Ramón Zapata highlighted the strategic value of collaborations, noting that the partnership payment from Bristol Myers Squibb “underscores the strategic value of our collaborations not only in the long term but also in the short term.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.